Abstract
In a randomized controlled study of 55 hypertensive patients, xuezhikang therapy resulted in significant reductions in serum and urine β2-microglobulin (β2-M), and serum immune complex (IC) compared with baseline, as well as with placebo. Urine α1-microglobulin (α1-M) and β2-M were positively correlated with serum IC and IgG by linear regression analysis, and only with serum IC on multivariate regression analysis. The data suggested that the significant modification of xuezhikang on urinary microglobulin excretion was probably associated with its immunomodulating effect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
